Tous Actualités
Suivre
Abonner Biosafe Group

Biosafe Group

Biosafe inaugurates its expanded China business

Switzerland (ots)

Following the full registration of its product range by the Chinese FDA last April, Biosafe is gearing up its activities in the People's Republic of China with a major expansion of its Shanghai-based operations, including staffing and facilities consolidation. Such expansion will enable Biosafe to support the many new developments in China within the Cord Blood Banking, Regenerative Medicine and Bioprocessing markets where the Group holds leadership.

To mark this significant business extension, Biosafe is today holding an official celebration event at the Grand Hyatt Hotel Shanghai, with a conference on stem cell therapy that will include a keynote presentation from Dr. Joanne Kurtzberg (Director, Pediatric Blood and Marrow Transplant Program, Duke University, USA).

Olivier Waridel, CEO of the Biosafe Group commented: "This expansion of our China operations underlines the commitment of Biosafe to cooperate with the Chinese cell therapy community, by working more closely with our clients and scientific partners in the People's Republic of China. Biosafe looks forward to further developing close relationships with them and is enthusiastic about jointly supporting their efforts".

About the Biosafe Group

Founded in 1997 the Biosafe Group is active in the design, manufacture and marketing of automated cell processing systems. Headquartered in Switzerland and privately-owned, the Biosafe Group operates through regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and São Paulo) and is present in more than 50 countries, either directly or through distributors.

Contact:

Christopher Bolton
CFO
Biosafe Group SA
+41-22-365-27-27
christopher.bolton@biosafe.ch
www.biosafe.ch

Plus de actualités: Biosafe Group
Plus de actualités: Biosafe Group
  • 05.06.2014 – 07:00

    Biosafe introduces a brand new cell separator

    Eysins (ots) - In line with its mission of market innovator, Biosafe is proud to announce the launch of the SepaMax multiprocessing device, on the occasion of the International Cord Blood Symposium in San Francisco. SepaMax is designed for high throughput cell processing. Based on Biosafe's industry-leading Sepax technology, it offers six processing modules in a compact package, which are centrally controlled. Combined ...

  • 08.04.2014 – 07:00

    Biosafe achieves full registration in China

    Eysins, Switzerland (ots) - Biosafe is proud to report that it has just received the official registration of its single use disposable kits with the Chinese FDA. Following earlier approval of the Company's Sepax cell processing machine, Biosafe is now primed to launch sales of its products in the People's Republic of China. Olivier Waridel, CEO of the Biosafe Group commented: "We are the only company in our field which ...

  • 12.12.2013 – 07:00

    BIOSAFE targets Latin American expansion

    Eysins, Switzerland (ots) - Following the set-up of a Shanghai-based Chinese subsidiary and its recent expansion in India, Biosafe is demonstrating its firm commitment to emerging markets with the creation of a new subsidiary and the opening today of a new office covering the Latin American area. The new company, Biosafe do Brasil Participaçôes e Representações Ltda., based in the Vila Olímpia quarter of São Paulo ...